ArticleFrontiers in chemistry2025
Topological insights into breast cancer drugs: a QSPR approach using resolving topological indices.
Article in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Integrating Machine Learning Approaches and Topological Indices for Prediction of Electronic Properties in Anticancer Drugs.ACS omega · 2026Article
- Exploring anticancer drug structures through vertex based resolving parameters.Scientific reports · 2026Article
- Chromatic hyper Zagreb topological descriptors and QSPR analysis of certain skin cancer drugs.Frontiers in chemistry · 2026Article
- Eccentricity-based topological indices of QSPR modelling using anti-cancer drugs.Frontiers in chemistry · 2026Article
- Structure-efficiency relationship of access group antibiotics via SK chromatic descriptors.Frontiers in chemistry · 2026Article
- QSPR analysis of the drugs used to treat major depressive disorder using degree and neighborhood degree based indices.Frontiers in chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer, one of the most prevalent malignancies in women begins in the milk ducts or lobules and is divided into invasive and non-invasive variants. The kind stage and molecular features of the cancer determine the treatment strategy which may include surgery, chemotherapy, and targeted drugs. Early identification through screening is critical to increasing patient survival rates. Methods: In this study, we look at the efficacy of numerous breast cancer drugs, including Toremifene, Tucatinib, Ribociclib, Olaparib, Abemaciclib, Anastrozole, Letrozole, Thiotepa, Tamoxifen, and Megestrol Acetate. We investigate their chemical and physical properties, including molar volume (MV), polarizability (P), molar refractivity (MR), polar surface area (PSA), and surface tension (ST). We employ Quantitative Structure Property Relationship (QSPR) analytical approaches, including curvilinear regression and multiple linear regression (MLR), to model and predict the physicochemical properties of these medications by analyzing the impact of molecular descriptors on these properties. Results: A comparison of the two regression techniques is done to see how accurate their predictions are and to find the best way to model the data. Furthermore, resolving topological indices examines the relationship between molecular structure and therapeutic effectiveness. Discussion: The outcomes of these studies help to further our understanding of breast cancer treatments and the development of more focused and customized therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.